Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
  1. Home
  2. Publications
  3. Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Authors:
  • AEArielle Elkrief
    Arielle Elkrief
  • AMAlex Makhnin
    Alex Makhnin
  • KMKhadeja A. Moses
    Khadeja A. Moses
  • LALinda S. Ahn
    Linda S. Ahn
  • IPIsabel R. Preeshagul
    Isabel R. Preeshagul
  • AIAfsheen N. Iqbal
    Afsheen N. Iqbal
  • SHSara A. Hayes
    Sara A. Hayes
  • APAndrew J. Plodkowski
    Andrew J. Plodkowski
  • PPPaul K. Paik
    Paul K. Paik
  • MLMarc Ladanyi
    Marc Ladanyi
  • MKMark G. Kris
    Mark G. Kris
  • GRGregory J. Riely
    Gregory J. Riely

Open Access
Publisher website
Google Scholar
  • 25 November 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.30707384
Abstract
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study
Keywords
  • CLINICAL TRIAL RESULTS
  • PHASE II CLINICAL TRIALS
  • DRUG TARGETS
  • CELL SURFACE RECEPTOR DRUG TARGETS
  • LUNG CANCER
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.